Alnylam Pharmaceuticals
ALNY
$145.16
Share price
-0.11%
Change (1 day)
-28.02%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) Fails to deliver data
Key failure to deliver metrics for Alnylam Pharmaceuticals :
- Last SEC data release: 2024-03-28
- Last 15 days FTD volume: $0 M
- Last 3 months FTD volume: $15.22 M
- Last year FTD volume: $43.68 M
Failures to deliver for Alnylam Pharmaceuticals (ALNY) - 3 months history
Number of shares, 3 months chartBiweekly Failures to deliver volume for Alnylam Pharmaceuticals (ALNY) - since 2013
Volume in USD (price x number of shares), data since 2013Alnylam Pharmaceuticals (ALNY) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2024 | $15.22 M | -70.71% |
| 2023 | $51.99 M | -66.55% |
| 2022 | $0.15 B | 200.46% |
| 2021 | $51.74 M | -9.83% |
| 2020 | $57.38 M | 52.34% |
| 2019 | $37.66 M | 46.52% |
| 2018 | $25.7 M | -70.97% |
| 2017 | $88.54 M | 191.96% |
| 2016 | $30.32 M | -14.94% |
| 2015 | $35.65 M | 68.07% |
| 2014 | $21.21 M | 152.1% |
| 2013 | $8.41 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Novartis NVS | $30.53 M | $95.22 M | 🇨🇭 Switzerland |
 Sanofi SNY | $26.25 M | $54.4 M | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | $59.04 M | $0.14 B | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $6.44 M | $36.3 M | 🇺🇸 USA |
 Regulus Therapeutics RGLS | $2.28 M | $2.36 M | 🇺🇸 USA |
 OPKO Health
OPK | $39.65 M | $43.26 M | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $6.66 M | $42.47 M | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | $4.24 M | $8.64 M | 🇺🇸 USA |